# Use of Protamine for Heparin Reversal After Catheter Ablation of Atrial Fibrillation

Study · id `cardio:ct-nct03140631` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT03140631](<https://clinicaltrials.gov/study/NCT03140631>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT03140631

Browse, organ or system: Heart  
Browse, condition area: Stroke; Heart rhythm problems  

## In plain language

A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 153 participants.

## Technical summary

Registry record NCT03140631. Randomized; no masking; primary purpose treatment. Start 2017-03-23 (actual); primary completion 2017-11-16 (actual). Results posted on 2018-10-23.

## Key facts

- Design: Interventional study; randomized; no masking; primary purpose treatment
- Phase: Phase 4
- Enrolled: 153 participants (enrolled count; ClinicalTrials.gov record NCT03140631, source copy `cardio:ctgov-nct03140631-2018-10-23`, retrieved 2026-10-26)
- Started: 2017-03-23 (actual) (ClinicalTrials.gov record NCT03140631, source copy `cardio:ctgov-nct03140631-2018-10-23`, retrieved 2026-10-26)
- Primary completion: 2017-11-16 (actual) (ClinicalTrials.gov record NCT03140631, source copy `cardio:ctgov-nct03140631-2018-10-23`, retrieved 2026-10-26)
- Completion: 2018-04-03 (actual) (ClinicalTrials.gov record NCT03140631, source copy `cardio:ctgov-nct03140631-2018-10-23`, retrieved 2026-10-26)
- Results first posted: 2018-10-23 (ClinicalTrials.gov record NCT03140631, source copy `cardio:ctgov-nct03140631-2018-10-23`, retrieved 2026-10-26)
- Countries: United States (ClinicalTrials.gov record NCT03140631, source copy `cardio:ctgov-nct03140631-2018-10-23`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct03140631-2018-10-23`, retrieved 2026-10-26)

## The registry's words

- Brief title: Use of Protamine for Heparin Reversal After Catheter Ablation of Atrial Fibrillation
- Condition: Atrial Fibrillation
- Condition: Catheter Ablation
- Intervention (Drug): Protamine Sulfate
- Lead sponsor: University of Michigan
- Lead sponsor class: OTHER

## Connected pages

- Registry condition terms include this condition: Arrhythmia (heart rhythm problems) (`cardio:arrhythmia`)
- Registry condition terms include this condition: Atrial fibrillation (AF) (`cardio:atrial-fibrillation`)
- Registry lists this organization as the lead sponsor: University of Michigan (`cardio:org-university-of-michigan`)

## Provenance

Content hash: c562626d186c1886369489cd90ae9ed56f676f038ca83b551e335d143e4f70fa
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
